APO Research
Talk to an analyst

APO RESEARCH · REPORT

Non-iodinated X-ray Contrast Agents

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Non-iodinated X-ray Contrast Agents Market Outlook and Growth Opportunities 2026

27 December 2025194 pages

Choose your research edition.

Industry ResearchNon-iodinated X-ray Contrast Agents Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Non-iodinated X-ray Contrast Agents Industry Growth and Trends Forecast to 203293 pages · $3,450 USDMarket StructureGlobal Non-iodinated X-ray Contrast Agents Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Non-iodinated X-ray Contrast Agents Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Non-iodinated X-ray Contrast Agents Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Non-iodinated X-ray Contrast Agents market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Non-iodinated X-ray Contrast Agents is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Non-iodinated X-ray Contrast Agents is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Non-iodinated X-ray Contrast Agents is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Non-iodinated X-ray Contrast Agents market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Non-iodinated X-ray Contrast Agents market include Bracco Diagnostics, Guerbet Group, Qinhuangdao Zizhu Pharmaceutical Co., Ltd., Qingdao Hongdie New Materials Co., Ltd., Shandong Shengli Pharmaceutical Co., Ltd., Taishan Xinning Pharmaceutical Co., Ltd. and Xi'an Disai Biopharmaceutical Co., Ltd., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Non-iodinated X-ray Contrast Agents market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Non-iodinated X-ray Contrast Agents and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Non-iodinated X-ray Contrast Agents sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Non-iodinated X-ray Contrast Agents market size, projected growth trends, production technologies, key applications, and end-use industries.

Non-iodinated X-ray Contrast Agents Segment by Company

Bracco Diagnostics

Guerbet Group

Qinhuangdao Zizhu Pharmaceutical Co., Ltd.

Qingdao Hongdie New Materials Co., Ltd.

Shandong Shengli Pharmaceutical Co., Ltd.

Taishan Xinning Pharmaceutical Co., Ltd.

Xi'an Disai Biopharmaceutical Co., Ltd.

Non-iodinated X-ray Contrast Agents Segment by Type

Barium Sulfate Type I

Barium Sulfate Type II

Non-iodinated X-ray Contrast Agents Segment by Application

Hospital

Clinic

Other

Non-iodinated X-ray Contrast Agents Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Non-iodinated X-ray Contrast Agents status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Non-iodinated X-ray Contrast Agents market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Non-iodinated X-ray Contrast Agents significant trends, drivers, influence factors in global and regions.

6. To analyze Non-iodinated X-ray Contrast Agents competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Non-iodinated X-ray Contrast Agents market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Non-iodinated X-ray Contrast Agents and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Non-iodinated X-ray Contrast Agents.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Non-iodinated X-ray Contrast Agents market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Non-iodinated X-ray Contrast Agents industry.

Chapter 3: Detailed analysis of Non-iodinated X-ray Contrast Agents manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Non-iodinated X-ray Contrast Agents in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Non-iodinated X-ray Contrast Agents in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Non-iodinated X-ray Contrast Agents Industry Trends Table 2. Non-iodinated X-ray Contrast Agents Industry Drivers Table 3. Non-iodinated X-ray Contrast Agents Industry Opportunities and Challenges Table 4. Non-iodinated X-ray Contrast Agents Industry Restraints Table 5. Global Non-iodinated X-ray Contrast Agents Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Non-iodinated X-ray Contrast Agents Revenue Share by Company (2021-2026) Table 7. Global Non-iodinated X-ray Contrast Agents Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Non-iodinated X-ray Contrast Agents Sales Volume Share by Company (2021-2026) Table 9. Global Non-iodinated X-ray Contrast Agents Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Non-iodinated X-ray Contrast Agents Company Ranking, (2024-2026) & (USD Million) Table 11. Global Non-iodinated X-ray Contrast Agents Key Company Manufacturing Base & Headquarters Table 12. Global Non-iodinated X-ray Contrast Agents Company, Product Type & Application Table 13. Global Non-iodinated X-ray Contrast Agents Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Non-iodinated X-ray Contrast Agents by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Barium Sulfate Type I Table 18. Significant Companies of Barium Sulfate Type II Table 19. Global Non-iodinated X-ray Contrast Agents Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Non-iodinated X-ray Contrast Agents Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Non-iodinated X-ray Contrast Agents Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Non-iodinated X-ray Contrast Agents Sales Volume Share by Type (2021-2026) Table 23. Global Non-iodinated X-ray Contrast Agents Sales Volume Share by Type (2027-2032) Table 24. Global Non-iodinated X-ray Contrast Agents Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Non-iodinated X-ray Contrast Agents Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Non-iodinated X-ray Contrast Agents Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Non-iodinated X-ray Contrast Agents Sales Value Share by Type (2021-2026) Table 28. Global Non-iodinated X-ray Contrast Agents Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospital Table 30. Significant Companies of Clinic Table 31. Significant Companies of Other Table 32. Global Non-iodinated X-ray Contrast Agents Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Non-iodinated X-ray Contrast Agents Sales Volume by Application (2021-2026) & (K Units) Table 34. Global Non-iodinated X-ray Contrast Agents Sales Volume by Application (2027-2032) & (K Units) Table 35. Global Non-iodinated X-ray Contrast Agents Sales Volume Share by Application (2021-2026) Table 36. Global Non-iodinated X-ray Contrast Agents Sales Volume Share by Application (2027-2032) Table 37. Global Non-iodinated X-ray Contrast Agents Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Non-iodinated X-ray Contrast Agents Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Non-iodinated X-ray Contrast Agents Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Non-iodinated X-ray Contrast Agents Sales Value Share by Application (2021-2026) Table 41. Global Non-iodinated X-ray Contrast Agents Sales Value Share by Application (2027-2032) Table 42. Global Non-iodinated X-ray Contrast Agents Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Non-iodinated X-ray Contrast Agents Sales by Region (2021-2026) & (K Units) Table 44. Global Non-iodinated X-ray Contrast Agents Sales Market Share by Region (2021-2026) Table 45. Global Non-iodinated X-ray Contrast Agents Sales by Region (2027-2032) & (K Units) Table 46. Global Non-iodinated X-ray Contrast Agents Sales Market Share by Region (2027-2032) Table 47. Global Non-iodinated X-ray Contrast Agents Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Non-iodinated X-ray Contrast Agents Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Non-iodinated X-ray Contrast Agents Sales Value Share by Region (2021-2026) Table 50. Global Non-iodinated X-ray Contrast Agents Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Non-iodinated X-ray Contrast Agents Sales Value Share by Region (2027-2032) Table 52. Global Non-iodinated X-ray Contrast Agents Market Average Price (US$/Unit) by Region (2021-2026) Table 53. Global Non-iodinated X-ray Contrast Agents Market Average Price (US$/Unit) by Region (2027-2032) Table 54. Global Non-iodinated X-ray Contrast Agents Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Global Non-iodinated X-ray Contrast Agents Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Non-iodinated X-ray Contrast Agents Sales by Country (2021-2026) & (K Units) Table 57. Global Non-iodinated X-ray Contrast Agents Sales Market Share by Country (2021-2026) Table 58. Global Non-iodinated X-ray Contrast Agents Sales by Country (2027-2032) & (K Units) Table 59. Global Non-iodinated X-ray Contrast Agents Sales Market Share by Country (2027-2032) Table 60. Global Non-iodinated X-ray Contrast Agents Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Non-iodinated X-ray Contrast Agents Sales Value Market Share by Country (2021-2026) Table 62. Global Non-iodinated X-ray Contrast Agents Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Non-iodinated X-ray Contrast Agents Sales Value Market Share by Country (2027-2032) Table 64. Bracco Diagnostics Company Information Table 65. Bracco Diagnostics Business Overview Table 66. Bracco Diagnostics Non-iodinated X-ray Contrast Agents Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Bracco Diagnostics Non-iodinated X-ray Contrast Agents Product Portfolio Table 68. Bracco Diagnostics Recent Development Table 69. Guerbet Group Company Information Table 70. Guerbet Group Business Overview Table 71. Guerbet Group Non-iodinated X-ray Contrast Agents Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Guerbet Group Non-iodinated X-ray Contrast Agents Product Portfolio Table 73. Guerbet Group Recent Development Table 74. Qinhuangdao Zizhu Pharmaceutical Co., Ltd. Company Information Table 75. Qinhuangdao Zizhu Pharmaceutical Co., Ltd. Business Overview Table 76. Qinhuangdao Zizhu Pharmaceutical Co., Ltd. Non-iodinated X-ray Contrast Agents Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Qinhuangdao Zizhu Pharmaceutical Co., Ltd. Non-iodinated X-ray Contrast Agents Product Portfolio Table 78. Qinhuangdao Zizhu Pharmaceutical Co., Ltd. Recent Development Table 79. Qingdao Hongdie New Materials Co., Ltd. Company Information Table 80. Qingdao Hongdie New Materials Co., Ltd. Business Overview Table 81. Qingdao Hongdie New Materials Co., Ltd. Non-iodinated X-ray Contrast Agents Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Qingdao Hongdie New Materials Co., Ltd. Non-iodinated X-ray Contrast Agents Product Portfolio Table 83. Qingdao Hongdie New Materials Co., Ltd. Recent Development Table 84. Shandong Shengli Pharmaceutical Co., Ltd. Company Information Table 85. Shandong Shengli Pharmaceutical Co., Ltd. Business Overview Table 86. Shandong Shengli Pharmaceutical Co., Ltd. Non-iodinated X-ray Contrast Agents Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Shandong Shengli Pharmaceutical Co., Ltd. Non-iodinated X-ray Contrast Agents Product Portfolio Table 88. Shandong Shengli Pharmaceutical Co., Ltd. Recent Development Table 89. Taishan Xinning Pharmaceutical Co., Ltd. Company Information Table 90. Taishan Xinning Pharmaceutical Co., Ltd. Business Overview Table 91. Taishan Xinning Pharmaceutical Co., Ltd. Non-iodinated X-ray Contrast Agents Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Taishan Xinning Pharmaceutical Co., Ltd. Non-iodinated X-ray Contrast Agents Product Portfolio Table 93. Taishan Xinning Pharmaceutical Co., Ltd. Recent Development Table 94. Xi'an Disai Biopharmaceutical Co., Ltd. Company Information Table 95. Xi'an Disai Biopharmaceutical Co., Ltd. Business Overview Table 96. Xi'an Disai Biopharmaceutical Co., Ltd. Non-iodinated X-ray Contrast Agents Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Xi'an Disai Biopharmaceutical Co., Ltd. Non-iodinated X-ray Contrast Agents Product Portfolio Table 98. Xi'an Disai Biopharmaceutical Co., Ltd. Recent Development Table 99. Key Raw Materials Table 100. Raw Materials Key Suppliers Table 101. Non-iodinated X-ray Contrast Agents Distributors List Table 102. Non-iodinated X-ray Contrast Agents Customers List Table 103. Research Programs/Design for This Report Table 104. Authors List of This Report Table 105. Secondary Sources Table 106. Primary Sources List of Figures Figure 1. Non-iodinated X-ray Contrast Agents Product Image Figure 2. Global Non-iodinated X-ray Contrast Agents Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Non-iodinated X-ray Contrast Agents Sales Value (2021-2032) & (US$ Million) Figure 4. Global Non-iodinated X-ray Contrast Agents Sales (2021-2032) & (K Units) Figure 5. Global Non-iodinated X-ray Contrast Agents Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Non-iodinated X-ray Contrast Agents Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Barium Sulfate Type I Image Figure 10. Barium Sulfate Type II Image Figure 11. Global Non-iodinated X-ray Contrast Agents Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Non-iodinated X-ray Contrast Agents Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Non-iodinated X-ray Contrast Agents Sales Volume Share by Type (2021-2032) Figure 14. Global Non-iodinated X-ray Contrast Agents Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Non-iodinated X-ray Contrast Agents Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Non-iodinated X-ray Contrast Agents Sales Value Share by Type (2021-2032) Figure 17. Hospital Image Figure 18. Clinic Image Figure 19. Other Image Figure 20. Global Non-iodinated X-ray Contrast Agents Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Non-iodinated X-ray Contrast Agents Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Non-iodinated X-ray Contrast Agents Sales Volume Share by Application (2021-2032) Figure 23. Global Non-iodinated X-ray Contrast Agents Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Non-iodinated X-ray Contrast Agents Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Non-iodinated X-ray Contrast Agents Sales Value Share by Application (2021-2032) Figure 26. Global Non-iodinated X-ray Contrast Agents Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 27. Global Non-iodinated X-ray Contrast Agents Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Non-iodinated X-ray Contrast Agents Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Non-iodinated X-ray Contrast Agents Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Non-iodinated X-ray Contrast Agents Sales Value (2021-2032) & (US$ Million) Figure 31. North America Non-iodinated X-ray Contrast Agents Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Non-iodinated X-ray Contrast Agents Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Non-iodinated X-ray Contrast Agents Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Non-iodinated X-ray Contrast Agents Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Non-iodinated X-ray Contrast Agents Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Non-iodinated X-ray Contrast Agents Sales Value (2021-2032) & (US$ Million) Figure 37. South America Non-iodinated X-ray Contrast Agents Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Non-iodinated X-ray Contrast Agents Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Non-iodinated X-ray Contrast Agents Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Non-iodinated X-ray Contrast Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Non-iodinated X-ray Contrast Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Non-iodinated X-ray Contrast Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Non-iodinated X-ray Contrast Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Non-iodinated X-ray Contrast Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Non-iodinated X-ray Contrast Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Non-iodinated X-ray Contrast Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Non-iodinated X-ray Contrast Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Non-iodinated X-ray Contrast Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Non-iodinated X-ray Contrast Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Non-iodinated X-ray Contrast Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Non-iodinated X-ray Contrast Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Non-iodinated X-ray Contrast Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Non-iodinated X-ray Contrast Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Non-iodinated X-ray Contrast Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Non-iodinated X-ray Contrast Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Non-iodinated X-ray Contrast Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Non-iodinated X-ray Contrast Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Non-iodinated X-ray Contrast Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Non-iodinated X-ray Contrast Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Non-iodinated X-ray Contrast Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Non-iodinated X-ray Contrast Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Non-iodinated X-ray Contrast Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Non-iodinated X-ray Contrast Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Non-iodinated X-ray Contrast Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Non-iodinated X-ray Contrast Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Non-iodinated X-ray Contrast Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Non-iodinated X-ray Contrast Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Non-iodinated X-ray Contrast Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Non-iodinated X-ray Contrast Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Non-iodinated X-ray Contrast Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Non-iodinated X-ray Contrast Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Non-iodinated X-ray Contrast Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Non-iodinated X-ray Contrast Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Non-iodinated X-ray Contrast Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Non-iodinated X-ray Contrast Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Non-iodinated X-ray Contrast Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Non-iodinated X-ray Contrast Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Non-iodinated X-ray Contrast Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Non-iodinated X-ray Contrast Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Non-iodinated X-ray Contrast Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Non-iodinated X-ray Contrast Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Non-iodinated X-ray Contrast Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Non-iodinated X-ray Contrast Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Non-iodinated X-ray Contrast Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Non-iodinated X-ray Contrast Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Non-iodinated X-ray Contrast Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Non-iodinated X-ray Contrast Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Non-iodinated X-ray Contrast Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Non-iodinated X-ray Contrast Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Non-iodinated X-ray Contrast Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Non-iodinated X-ray Contrast Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Non-iodinated X-ray Contrast Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Non-iodinated X-ray Contrast Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Non-iodinated X-ray Contrast Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Non-iodinated X-ray Contrast Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Non-iodinated X-ray Contrast Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Non-iodinated X-ray Contrast Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Non-iodinated X-ray Contrast Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Non-iodinated X-ray Contrast Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Non-iodinated X-ray Contrast Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Non-iodinated X-ray Contrast Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Non-iodinated X-ray Contrast Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Non-iodinated X-ray Contrast Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Non-iodinated X-ray Contrast Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Non-iodinated X-ray Contrast Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Non-iodinated X-ray Contrast Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Non-iodinated X-ray Contrast Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Non-iodinated X-ray Contrast Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Non-iodinated X-ray Contrast Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Non-iodinated X-ray Contrast Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Non-iodinated X-ray Contrast Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Non-iodinated X-ray Contrast Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Non-iodinated X-ray Contrast Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Non-iodinated X-ray Contrast Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Non-iodinated X-ray Contrast Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Non-iodinated X-ray Contrast Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Non-iodinated X-ray Contrast Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Non-iodinated X-ray Contrast Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Non-iodinated X-ray Contrast Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Non-iodinated X-ray Contrast Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Non-iodinated X-ray Contrast Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Non-iodinated X-ray Contrast Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Non-iodinated X-ray Contrast Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Non-iodinated X-ray Contrast Agents Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Non-iodinated X-ray Contrast Agents Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Barium Sulfate Type I
  • Barium Sulfate Type II
Applications
  • Hospital
  • Clinic
  • Other
Companies covered
  • Bracco Diagnostics
  • Guerbet Group
  • Qinhuangdao Zizhu Pharmaceutical Co., Ltd.
  • Qingdao Hongdie New Materials Co., Ltd.
  • Shandong Shengli Pharmaceutical Co., Ltd.
  • Taishan Xinning Pharmaceutical Co., Ltd.
  • Xi'an Disai Biopharmaceutical Co., Ltd.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Non-iodinated X-ray Contrast Agents Sales Value (2021-2032)
  4. 1.2.2 Global Non-iodinated X-ray Contrast Agents Sales Volume (2021-2032)
  5. 1.2.3 Global Non-iodinated X-ray Contrast Agents Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Non-iodinated X-ray Contrast Agents Market Dynamics
  1. 2.1 Non-iodinated X-ray Contrast Agents Industry Trends
  2. 2.2 Non-iodinated X-ray Contrast Agents Industry Drivers
  3. 2.3 Non-iodinated X-ray Contrast Agents Industry Opportunities and Challenges
  4. 2.4 Non-iodinated X-ray Contrast Agents Industry Restraints
3 Non-iodinated X-ray Contrast Agents Market by Company
  1. 3.1 Global Non-iodinated X-ray Contrast Agents Company Revenue Ranking in 2025
  2. 3.2 Global Non-iodinated X-ray Contrast Agents Revenue by Company (2021-2026)
  3. 3.3 Global Non-iodinated X-ray Contrast Agents Sales Volume by Company (2021-2026)
  4. 3.4 Global Non-iodinated X-ray Contrast Agents Average Price by Company (2021-2026)
  5. 3.5 Global Non-iodinated X-ray Contrast Agents Company Ranking (2024-2026)
  6. 3.6 Global Non-iodinated X-ray Contrast Agents Company Manufacturing Base and Headquarters
  7. 3.7 Global Non-iodinated X-ray Contrast Agents Company Product Type and Application
  8. 3.8 Global Non-iodinated X-ray Contrast Agents Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Non-iodinated X-ray Contrast Agents Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Non-iodinated X-ray Contrast Agents Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Non-iodinated X-ray Contrast Agents Market by Type
  1. 4.1 Non-iodinated X-ray Contrast Agents Type Introduction
  2. 4.1.1 Barium Sulfate Type I
  3. 4.1.2 Barium Sulfate Type II
  4. 4.2 Global Non-iodinated X-ray Contrast Agents Sales Volume by Type
  5. 4.2.1 Global Non-iodinated X-ray Contrast Agents Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Non-iodinated X-ray Contrast Agents Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Non-iodinated X-ray Contrast Agents Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Non-iodinated X-ray Contrast Agents Sales Value by Type
  9. 4.3.1 Global Non-iodinated X-ray Contrast Agents Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Non-iodinated X-ray Contrast Agents Sales Value by Type (2021-2032)
  11. 4.3.3 Global Non-iodinated X-ray Contrast Agents Sales Value Share by Type (2021-2032)
5 Non-iodinated X-ray Contrast Agents Market by Application
  1. 5.1 Non-iodinated X-ray Contrast Agents Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Other
  5. 5.2 Global Non-iodinated X-ray Contrast Agents Sales Volume by Application
  6. 5.2.1 Global Non-iodinated X-ray Contrast Agents Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Non-iodinated X-ray Contrast Agents Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Non-iodinated X-ray Contrast Agents Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Non-iodinated X-ray Contrast Agents Sales Value by Application
  10. 5.3.1 Global Non-iodinated X-ray Contrast Agents Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Non-iodinated X-ray Contrast Agents Sales Value by Application (2021-2032)
  12. 5.3.3 Global Non-iodinated X-ray Contrast Agents Sales Value Share by Application (2021-2032)
6 Non-iodinated X-ray Contrast Agents Regional Sales and Value Analysis
  1. 6.1 Global Non-iodinated X-ray Contrast Agents Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Non-iodinated X-ray Contrast Agents Sales by Region (2021-2032)
  3. 6.2.1 Global Non-iodinated X-ray Contrast Agents Sales by Region: 2021-2026
  4. 6.2.2 Global Non-iodinated X-ray Contrast Agents Sales by Region (2027-2032)
  5. 6.3 Global Non-iodinated X-ray Contrast Agents Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Non-iodinated X-ray Contrast Agents Sales Value by Region (2021-2032)
  7. 6.4.1 Global Non-iodinated X-ray Contrast Agents Sales Value by Region: 2021-2026
  8. 6.4.2 Global Non-iodinated X-ray Contrast Agents Sales Value by Region (2027-2032)
  9. 6.5 Global Non-iodinated X-ray Contrast Agents Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Non-iodinated X-ray Contrast Agents Sales Value (2021-2032)
  12. 6.6.2 North America Non-iodinated X-ray Contrast Agents Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Non-iodinated X-ray Contrast Agents Sales Value (2021-2032)
  15. 6.7.2 Europe Non-iodinated X-ray Contrast Agents Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Non-iodinated X-ray Contrast Agents Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Non-iodinated X-ray Contrast Agents Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Non-iodinated X-ray Contrast Agents Sales Value (2021-2032)
  21. 6.9.2 South America Non-iodinated X-ray Contrast Agents Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Non-iodinated X-ray Contrast Agents Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Non-iodinated X-ray Contrast Agents Sales Value Share by Country, 2025 VS 2032
7 Non-iodinated X-ray Contrast Agents Country-level Sales and Value Analysis
  1. 7.1 Global Non-iodinated X-ray Contrast Agents Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Non-iodinated X-ray Contrast Agents Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Non-iodinated X-ray Contrast Agents Sales by Country (2021-2032)
  4. 7.3.1 Global Non-iodinated X-ray Contrast Agents Sales by Country (2021-2026)
  5. 7.3.2 Global Non-iodinated X-ray Contrast Agents Sales by Country (2027-2032)
  6. 7.4 Global Non-iodinated X-ray Contrast Agents Sales Value by Country (2021-2032)
  7. 7.4.1 Global Non-iodinated X-ray Contrast Agents Sales Value by Country (2021-2026)
  8. 7.4.2 Global Non-iodinated X-ray Contrast Agents Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Non-iodinated X-ray Contrast Agents Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Non-iodinated X-ray Contrast Agents Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Non-iodinated X-ray Contrast Agents Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Non-iodinated X-ray Contrast Agents Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Non-iodinated X-ray Contrast Agents Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Non-iodinated X-ray Contrast Agents Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Non-iodinated X-ray Contrast Agents Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Non-iodinated X-ray Contrast Agents Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Non-iodinated X-ray Contrast Agents Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Non-iodinated X-ray Contrast Agents Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Non-iodinated X-ray Contrast Agents Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Non-iodinated X-ray Contrast Agents Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Non-iodinated X-ray Contrast Agents Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Non-iodinated X-ray Contrast Agents Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Non-iodinated X-ray Contrast Agents Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Non-iodinated X-ray Contrast Agents Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Non-iodinated X-ray Contrast Agents Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Non-iodinated X-ray Contrast Agents Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Non-iodinated X-ray Contrast Agents Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Non-iodinated X-ray Contrast Agents Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Non-iodinated X-ray Contrast Agents Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Non-iodinated X-ray Contrast Agents Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Non-iodinated X-ray Contrast Agents Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Non-iodinated X-ray Contrast Agents Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Non-iodinated X-ray Contrast Agents Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Non-iodinated X-ray Contrast Agents Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Non-iodinated X-ray Contrast Agents Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Non-iodinated X-ray Contrast Agents Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Non-iodinated X-ray Contrast Agents Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Non-iodinated X-ray Contrast Agents Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Non-iodinated X-ray Contrast Agents Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Non-iodinated X-ray Contrast Agents Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Non-iodinated X-ray Contrast Agents Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Non-iodinated X-ray Contrast Agents Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Non-iodinated X-ray Contrast Agents Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Non-iodinated X-ray Contrast Agents Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Non-iodinated X-ray Contrast Agents Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Non-iodinated X-ray Contrast Agents Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Non-iodinated X-ray Contrast Agents Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Non-iodinated X-ray Contrast Agents Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Non-iodinated X-ray Contrast Agents Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Non-iodinated X-ray Contrast Agents Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Non-iodinated X-ray Contrast Agents Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Non-iodinated X-ray Contrast Agents Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Non-iodinated X-ray Contrast Agents Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Non-iodinated X-ray Contrast Agents Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Non-iodinated X-ray Contrast Agents Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Non-iodinated X-ray Contrast Agents Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Non-iodinated X-ray Contrast Agents Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Non-iodinated X-ray Contrast Agents Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Non-iodinated X-ray Contrast Agents Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Non-iodinated X-ray Contrast Agents Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Non-iodinated X-ray Contrast Agents Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Non-iodinated X-ray Contrast Agents Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Non-iodinated X-ray Contrast Agents Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Non-iodinated X-ray Contrast Agents Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Non-iodinated X-ray Contrast Agents Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Non-iodinated X-ray Contrast Agents Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Non-iodinated X-ray Contrast Agents Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Non-iodinated X-ray Contrast Agents Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Non-iodinated X-ray Contrast Agents Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Non-iodinated X-ray Contrast Agents Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Non-iodinated X-ray Contrast Agents Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Non-iodinated X-ray Contrast Agents Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Non-iodinated X-ray Contrast Agents Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Non-iodinated X-ray Contrast Agents Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Non-iodinated X-ray Contrast Agents Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Non-iodinated X-ray Contrast Agents Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Non-iodinated X-ray Contrast Agents Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Non-iodinated X-ray Contrast Agents Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Non-iodinated X-ray Contrast Agents Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Non-iodinated X-ray Contrast Agents Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Non-iodinated X-ray Contrast Agents Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Non-iodinated X-ray Contrast Agents Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Non-iodinated X-ray Contrast Agents Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Non-iodinated X-ray Contrast Agents Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Non-iodinated X-ray Contrast Agents Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Non-iodinated X-ray Contrast Agents Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Non-iodinated X-ray Contrast Agents Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Non-iodinated X-ray Contrast Agents Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Non-iodinated X-ray Contrast Agents Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Non-iodinated X-ray Contrast Agents Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Non-iodinated X-ray Contrast Agents Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Non-iodinated X-ray Contrast Agents Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Bracco Diagnostics
  2. 8.1.1 Bracco Diagnostics Company Information
  3. 8.1.2 Bracco Diagnostics Business Overview
  4. 8.1.3 Bracco Diagnostics Non-iodinated X-ray Contrast Agents Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Bracco Diagnostics Non-iodinated X-ray Contrast Agents Product Portfolio
  6. 8.1.5 Bracco Diagnostics Recent Developments
  7. 8.2 Guerbet Group
  8. 8.2.1 Guerbet Group Company Information
  9. 8.2.2 Guerbet Group Business Overview
  10. 8.2.3 Guerbet Group Non-iodinated X-ray Contrast Agents Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Guerbet Group Non-iodinated X-ray Contrast Agents Product Portfolio
  12. 8.2.5 Guerbet Group Recent Developments
  13. 8.3 Qinhuangdao Zizhu Pharmaceutical Co., Ltd.
  14. 8.3.1 Qinhuangdao Zizhu Pharmaceutical Co., Ltd. Company Information
  15. 8.3.2 Qinhuangdao Zizhu Pharmaceutical Co., Ltd. Business Overview
  16. 8.3.3 Qinhuangdao Zizhu Pharmaceutical Co., Ltd. Non-iodinated X-ray Contrast Agents Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Qinhuangdao Zizhu Pharmaceutical Co., Ltd. Non-iodinated X-ray Contrast Agents Product Portfolio
  18. 8.3.5 Qinhuangdao Zizhu Pharmaceutical Co., Ltd. Recent Developments
  19. 8.4 Qingdao Hongdie New Materials Co., Ltd.
  20. 8.4.1 Qingdao Hongdie New Materials Co., Ltd. Company Information
  21. 8.4.2 Qingdao Hongdie New Materials Co., Ltd. Business Overview
  22. 8.4.3 Qingdao Hongdie New Materials Co., Ltd. Non-iodinated X-ray Contrast Agents Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Qingdao Hongdie New Materials Co., Ltd. Non-iodinated X-ray Contrast Agents Product Portfolio
  24. 8.4.5 Qingdao Hongdie New Materials Co., Ltd. Recent Developments
  25. 8.5 Shandong Shengli Pharmaceutical Co., Ltd.
  26. 8.5.1 Shandong Shengli Pharmaceutical Co., Ltd. Company Information
  27. 8.5.2 Shandong Shengli Pharmaceutical Co., Ltd. Business Overview
  28. 8.5.3 Shandong Shengli Pharmaceutical Co., Ltd. Non-iodinated X-ray Contrast Agents Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Shandong Shengli Pharmaceutical Co., Ltd. Non-iodinated X-ray Contrast Agents Product Portfolio
  30. 8.5.5 Shandong Shengli Pharmaceutical Co., Ltd. Recent Developments
  31. 8.6 Taishan Xinning Pharmaceutical Co., Ltd.
  32. 8.6.1 Taishan Xinning Pharmaceutical Co., Ltd. Company Information
  33. 8.6.2 Taishan Xinning Pharmaceutical Co., Ltd. Business Overview
  34. 8.6.3 Taishan Xinning Pharmaceutical Co., Ltd. Non-iodinated X-ray Contrast Agents Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Taishan Xinning Pharmaceutical Co., Ltd. Non-iodinated X-ray Contrast Agents Product Portfolio
  36. 8.6.5 Taishan Xinning Pharmaceutical Co., Ltd. Recent Developments
  37. 8.7 Xi'an Disai Biopharmaceutical Co., Ltd.
  38. 8.7.1 Xi'an Disai Biopharmaceutical Co., Ltd. Company Information
  39. 8.7.2 Xi'an Disai Biopharmaceutical Co., Ltd. Business Overview
  40. 8.7.3 Xi'an Disai Biopharmaceutical Co., Ltd. Non-iodinated X-ray Contrast Agents Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Xi'an Disai Biopharmaceutical Co., Ltd. Non-iodinated X-ray Contrast Agents Product Portfolio
  42. 8.7.5 Xi'an Disai Biopharmaceutical Co., Ltd. Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Non-iodinated X-ray Contrast Agents Value Chain Analysis
  2. 9.1.1 Non-iodinated X-ray Contrast Agents Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Non-iodinated X-ray Contrast Agents Sales Mode & Process
  6. 9.2 Non-iodinated X-ray Contrast Agents Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Non-iodinated X-ray Contrast Agents Distributors
  9. 9.2.3 Non-iodinated X-ray Contrast Agents Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst